Brain Cancer

Data from the phase 3 ROADS trial show significant gains in efficacy without increases in safety concerns following the use of GammaTile.

A patient case of a 76-year-old man with a rare glioblastoma variant showcased the importance of molecular profiling in diagnosing and guiding treatment for brain tumors.

Results from a pilot phase 2 trial showed that all 5 patients who received treatment achieved a response or had stable disease.

Historical standards for H3K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.

Supporting data for the accelerated approval of dordaviprone come from 5 open-label trials in H3 K27M-mutant diffuse midline glioma.

Updated guidelines from ASTRO recommend various radiation therapy techniques for patients with WHO grade 4 adult-type diffuse glioma.

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

“Dendritic cell vaccines, CAR T-cell therapy, and things of that nature are holding some promise,” said Andrew Brenner, MD, PhD.

Andrew Brenner, MD, PhD, stated that rhenium obisbemeda elicited similar results in leptomeningeal disease as it did in recurrent glioma.

Patients with recurrent glioblastoma who had an absorbed dose of greater than 100 Gy with rhenium obisbemeda had a median overall survival of 17 months.

According to Andrew Brenner, MD, PhD, rhenium obisbemeda can be detected via SPECT imaging and aids in the care of patients with glioblastoma.

The developer plans to share top-line results for RAD101 in various solid tumors from the supporting phase 2b trial in the second half of 2025.

The safety profile of iopofosine I 131 in the phase 1b CLOVER-2 trial appears consistent with prior reports of the agent.

Specialties including neurosurgery, radiation oncology, and neurorehabilitation all play a notable role in the care of patients with brain tumors.

Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.

CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.

Andrew Brenner, MD, PhD, discussed rhenium obisbemeda and results from the ReSPECT-GBM trial for patients with glioblastoma.

Jennifer Moliterno, MD, FAANS, discusses effective collaboration strategies with multidisciplinary colleagues to optimize treatment for brain tumors.

The B7-H3 CAR T-cell therapy showed positive survival results for younger patients with diffuse intrinsic pontine glioma in a phase 1 trial.

Jennifer Moliterno, MD, FAANS, highlights post-operative complications that may arise after neurosurgery.

AI has the potential to change practice patterns, improve imaging, and inform treatment planning for patients with brain tumors.

Jennifer Moliterno, MD, FAANS, discusses current neurosurgical strategies for maximizing safe resection in newly diagnosed high-grade gliomas.

Oncology clinicians can effectively collaborate with neuroradiologists using advanced techniques to improve brain tumor characterization.

Jennifer Moliterno, MD, FAANS, discusses current neurosurgical strategies for newly diagnosed high-grade gliomas.

Nicholas Blondin, MD, discusses the latest advancements in immunotherapy for brain cancer as well as emerging strategies, including CAR T-cell therapy.